367 related articles for article (PubMed ID: 30291246)
1. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Meliani A; Boisgerault F; Hardet R; Marmier S; Collaud F; Ronzitti G; Leborgne C; Costa Verdera H; Simon Sola M; Charles S; Vignaud A; van Wittenberghe L; Manni G; Christophe O; Fallarino F; Roy C; Michaud A; Ilyinskii P; Kishimoto TK; Mingozzi F
Nat Commun; 2018 Oct; 9(1):4098. PubMed ID: 30291246
[TBL] [Abstract][Full Text] [Related]
2. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
3. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.
Unzu C; Hervás-Stubbs S; Sampedro A; Mauleón I; Mancheño U; Alfaro C; de Salamanca RE; Benito A; Beattie SG; Petry H; Prieto J; Melero I; Fontanellas A
J Transl Med; 2012 Jun; 10():122. PubMed ID: 22704060
[TBL] [Abstract][Full Text] [Related]
4. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
Hamilton BA; Wright JF
Front Immunol; 2021; 12():675897. PubMed ID: 34084173
[TBL] [Abstract][Full Text] [Related]
5. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.
Kuranda K; Jean-Alphonse P; Leborgne C; Hardet R; Collaud F; Marmier S; Costa Verdera H; Ronzitti G; Veron P; Mingozzi F
J Clin Invest; 2018 Dec; 128(12):5267-5279. PubMed ID: 30352429
[TBL] [Abstract][Full Text] [Related]
6. Effect of CpG Depletion of Vector Genome on CD8
Bertolini TB; Shirley JL; Zolotukhin I; Li X; Kaisho T; Xiao W; Kumar SRP; Herzog RW
Front Immunol; 2021; 12():672449. PubMed ID: 34135899
[TBL] [Abstract][Full Text] [Related]
7. Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.
Cramer ML; Shao G; Rodino-Klapac LR; Chicoine LG; Martin PT
Hum Gene Ther; 2017 Jun; 28(6):493-509. PubMed ID: 28345428
[TBL] [Abstract][Full Text] [Related]
8. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
9. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to adeno-associated virus vectors.
Zaiss AK; Muruve DA
Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
[TBL] [Abstract][Full Text] [Related]
11. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.
Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H
Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485
[TBL] [Abstract][Full Text] [Related]
12. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
14. Preclinical models to assess the immunogenicity of AAV vectors.
Ertl HCJ
Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
[TBL] [Abstract][Full Text] [Related]
15. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
16. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.
Lin J; Calcedo R; Vandenberghe LH; Figueredo JM; Wilson JM
Hum Gene Ther; 2008 Jul; 19(7):663-9. PubMed ID: 18549307
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
19. Regulatory and Exhausted T Cell Responses to AAV Capsid.
Gernoux G; Wilson JM; Mueller C
Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
